Institution statistics

MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN - Germany 

Ranking results:

Past rankings:
2019
Criterium:Position:
Overall Score:> 1000
Total Number of Projects:600-700
2018
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:600-700
Networking Rank (Reputation):> 1000
2016
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
Ranking timeline:

European project participation (2010-01-01 - 2021-12-31 ):

Performance:

Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:
Leadership:

Total number of projects: 19
As coordinator: 1
As participant: 18
Sole participant: 0
Coordinator / Participant Ratio: 0.06*

*Ratio includes only projects with > 2 partners

Summary:
Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2021 0 2.281.840 0 1
2019 0 77.525.204 0 5
2018 0 30.751.188 505.577 4
2017 3.556.208 23.549.833 1.471.729 1 2
2016 0 21.066.307 750.570 5
2010 0 23.073.794 184.549 1
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:
Institution:Projects [No]:
JANSSEN PHARMACEUTICA NV9
NOVARTIS PHARMA8
KATHOLIEKE UNIVERSITEIT LEUVEN7
PFIZER LIMITED6
BOEHRINGER INGELHEIM PHARMA GMBH &CO KG5
ELI LILLY AND COMPANY LIMITED5
F HOFFMANNLA ROCHE5
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT5
ABBVIE INC4
BAYER4
BAYER AKTIENGESELLSCHAFT4
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER4
MERCK SHARP & DOHME CORP4
SANOFIAVENTIS4
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD4
UCB BIOPHARMA4
AMGEN LIMITED3
ASTRAZENECA AB3
COVANCE LABORATORIES3
EUROPEAN PATIENTS' FORUM3
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E V3
GRUNENTHAL3
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE3
INSTITUT DE RECHERCHES SERVIER3
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE3
NOVO NORDISK3
SANOFIAVENTIS RECHERCHE & DEVELOPPEMENT3
TAKEDA DEVELOPMENT CENTRE EUROPE3
UNIVERSITAIR MEDISCH CENTRUM UTRECHT3
UNIVERSITY OF BIRMINGHAM3
UNIVERSITY OF NEWCASTLE UPON TYNE3
ARKEMA FRANCE2
ASTELLAS PHARMA EUROPE BV2
ASTRAZENECA2
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS2
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE2
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM2
ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON2
EUROPEAN CANCER PATIENT COALITION2
EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE2
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL2
FEDERATION EUROPEENNE D'ASSOCIATIONS ET D'INDUSTRIES PHARMACEUTIQUES2
FRIEDRICHALEXANDERUNIVERSITAET ERLANGEN NUERNBERG2
H LUNDBECK AS2
LEIDS UNIVERSITAIR MEDISCH CENTRUM2
MEDIZINISCHE UNIVERSITAT INNSBRUCK2
OLEON NV2
OWKIN FRANCE2
PROCESS DESIGN CENTER BV2
SANOFIAVENTIS DEUTSCHLAND2
STATENS LEGEMIDDELVERK2
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL2
SYNCOM BV2
TEVA PHARMACEUTICAL INDUSTRIES LIMITED2
THE ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY2
THE EUROPEAN MEDICINES AGENCY2
THE SYNERGIST2
THE UNIVERSITY OF MANCHESTER2
UNIVERSITAET ZUERICH2
UNIVERSITATSKLINIKUM ERLANGEN2
UNIVERSITE DE GENEVE2
UNIVERSITY COLLEGE CORK NATIONAL UNIVERSITY OF IRELAND CORK2
UNIVERSITY OF BOLOGNA2
UNIVERSITY OF DURHAM2
UNIVERSITY OF OSLO2
UPPSALA UNIVERSITET2
VERBAND FORSCHENDER ARZNEIMITTELHERSTELLER EV2
ABBVIE1
ACADEMISCH ZIEKENHUIS GRONINGEN1
ACCELOPMENT1
ACTA1
ACTELION PHARMACEUTICALS1
ADELPHI VALUES1
AGENZIA ITALIANA DEL FARMACO1
AGENZIA REGIONALE DI SANITA1
ALEXION SERVICES EUROPE SPRL1
ALZHEIMER EUROPE1
AMGEN1
AMGEN RESEARCH1
ASOCIACION NACIONAL EMPRESARIAL DE LA INDUSTRIA FARMACEUTICA1
AYMING1
BASF SE1
BAYER PHARMA1
BAYERISCHE FORSCHUNGSALLIANZ BAVARIAN RESEARCH ALLIANCE1
BIOASCENT DISCOVERY LIMITED1
BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM1
BIONOTUS1
BIOSCI CONSULTING BVBA1
BKW BIOKRAFTWERKE FUERSTENWALDE1
BLUEBIRD BIO INC1
BORREGAARD INDUSTRIES LIMITED1
BRISTOLMYERS SQUIBB COMPANY CORP1
BUDAPEST UNIVERSITY OF TECHNOLOGY AND ECONOMICS1
BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL1
CELGENE MANAGEMENT SARL1
CENTRE DE LUTTE CONTRE LE CANCER LEON BERARD1
CENTRE DE RECHERCHE PUBLIC DE LA SANTE1
CENTRE DE REGULACIO GENOMICA1
CENTRE FOR RENEWABLE ENERGY SOURCESAND SAVING FONDATION1
CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER1
Constancy:

Total number of partners:447

Partner loyalty:
Frequent Partner: (> 2 projects): 127
Rare Partner: 320

Frequent / Rare Partner Ratio: 0.4

Diversity:

Subjects:
Subject:No:
BIOFUELS1
SUSTAINABLE DEVELOPMENT1
Diversity index:0.43
Categories:
Category:No:
ENERGY1
PROTECTING MAN AND HIS ENVIRON1

Project overview:

Start dateProjectacronymrolefundingpartners
2021-01-01Establishing international standards in the analysis of patient reported outcomes and health-related quality of life data in cancer clinical trials SISAQOL-IMIparticipant2.281.84033
2019-12-01Immune Safety Avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies imSAVARparticipant10.999.31628
2019-06-01MachinE Learning Ledger Orchestration for Drug DiscoverY MELLODDYparticipant8.000.00017
2019-04-01Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation ConcePTIONparticipant15.299.99153
2019-04-01Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement MOBILISE-Dparticipant25.395.89734
2019-03-01Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts IMMUcanparticipant17.830.00028
2018-12-01European Screening Centre; Unique Library for Attractive Biology ESCulabparticipant18.249.99320
2018-11-01Chemical Engineering Immersive Learning CHARMINGparticipant4.060.22813
2018-10-01Using the smart matrix approach to enhance TADF-OLED efficiency and lifetime TADFlifeparticipant3.942.03721
2018-03-01Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes. PARADIGMparticipant4.498.93134
2017-09-01Enhacing TRANslational SAFEty Assessment through Integrative Knowledge Management eTRANSAFEparticipant20.000.00027
2017-02-01Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation - Sofia ref.: 116055 DO-ITparticipant3.549.83336
2017-01-01Development of high-performance, hyperfluorescence OLEDs for use in display applications and solid state lighting HyperOLEDcoordinator3.556.2085
2016-10-01Continuous Resolution and Deracemization of Chiral Compounds by Crystallization COREparticipant3.920.69015
2016-10-01Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 PREFERparticipant6.000.00033
2016-09-01Targeting SYNthetic lethal interactions for new cancer treatments TRAINing network SYNTRAINparticipant3.990.26913
2016-05-01Pharmaceutical Education And Research with Regulatory Links: Innovative drug development strategies and regulatory tools tailored to facilitate earlier access to medicines PEARRLparticipant3.856.25310
2016-02-01Production technology to achieve low Cost and Highly Efficient phOtovoltaic Perovskite Solar cells CHEOPSparticipant3.299.09512
2010-03-01EUROpean multilevel integrated BIOREFinery design for sustainable biomass processing EuroBioRefparticipant23.073.79434
Data provision: © European Union; Source: CORDIS, http://cordis.europa.eu/ | This page is not provided by the European Commission see:Impressum